Saturday, May 18, 2024
HomeFunding MA-based ArkeaBio Secures $26.5Million in Series A Round Funding

[Funding News] MA-based ArkeaBio Secures $26.5Million in Series A Round Funding

ArkeaBio™, a leading ag-biotech start-up developing, a vaccine to reduce livestock methane emissions, today announced the close of a $26.5 million Series A financing round.

ArkeaBio™, a leading ag-biotech start-up developing, a vaccine to reduce livestock methane emissions, secures a $26.5 million Series A financing round.

The raise was led by current investor Breakthrough Energy Ventures (BEV), and attracted additional investors, including The Grantham Foundation for the Protection of the Environment, AgriZeroNZ, Rabo Ventures, Overview Capital, and The51 Food &
AgTech Fund.

Read also – [Funding News] CA-based Bleach Cyber Secures $2Million in Pre-Seed Round Funding

ArkeaBio’s vaccine will provide an innovative, cost-effective, and scalable solution to reduce the world’s livestock methane emissions, which currently generate the equivalent of 3 Billion Tonnes of CO2 annually and represent 6% of annual Greenhouse gas emissions.

Chris Rivest, Chairman of the Board at ArkeaBio and partner at Breakthrough Energy Ventures said, “Reducing methane emissions from the agricultural sector is one of the most pressing challenges in today’s fight against climate change, ArkeaBio’s approach using innovative vaccine technologies will create effective and massively scalable solutions to reduce on-farm methane emissions, leaving them well-positioned to redefine the agricultural landscape in the years to come.”

ArkeaBio research and development results have garnered substantial attention from investors for the advancement of the inaugural methane-reducing vaccine, designed for safe and rapid implementation within existing on-farm practices.

The funds raised in this Series A financing will play a pivotal role in expanding the research, development and deployment of the vaccine, including large-scale field trials and engagement along the supply chain.

Colin South, ArkeaBio CEO said, “We are thankful for the financial support, confidence, and trust of our investors. This funding will accelerate the development of our vaccine-based solution to meet a pressing global problem, To echo the sentiments of The Grantham Foundation: ‘climate change is the greatest challenge humanity has ever faced. It is the race of our lives.’ This capital raise allows us to continue to create the tools necessary for farmers to achieve globally relevant reductions in livestock methane emissions.”

About Arkeabio™

ArkeaBio™ is an ag-biotech start-up developing a safe, user-friendly, and cost-conscious vaccine to reduce ruminant methane emissions that will work seamlessly with existing global agribusiness practices.

With a record of success and a growing reputation in the industry, ArkeaBio has emerged as a leading player known for its cutting-edge solutions, ground-breaking research, and unwavering commitment to changing the sustainable agricultural landscape as we know it.

- Advertisement -
RELATED ARTICLES
- Advertisment -

Most Popular